News | May 05, 2026
SK Capital sells Noramco assets to Siegfried
Keeps Halo Pharma to drive independent growth
Keeps Halo Pharma to drive independent growth
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Gambhir brings over 35 years of rich experience in strategic finance, governance, business transformation, and leadership
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The company allocated €56 million to research and development for next-generation line solutions
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Subscribe To Our Newsletter & Stay Updated
